BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 22798675)

  • 1. A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice.
    Mehrotra S; Al-Khami AA; Klarquist J; Husain S; Naga O; Eby JM; Murali AK; Lyons GE; Li M; Spivey ND; Norell H; Martins da Palma T; Onicescu G; Diaz-Montero CM; Garrett-Mayer E; Cole DJ; Le Poole IC; Nishimura MI
    J Immunol; 2012 Aug; 189(4):1627-38. PubMed ID: 22798675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD8-independent tumor cell recognition is a property of the T cell receptor and not the T cell.
    Roszkowski JJ; Yu DC; Rubinstein MP; McKee MD; Cole DJ; Nishimura MI
    J Immunol; 2003 Mar; 170(5):2582-9. PubMed ID: 12594285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.
    Roszkowski JJ; Lyons GE; Kast WM; Yee C; Van Besien K; Nishimura MI
    Cancer Res; 2005 Feb; 65(4):1570-6. PubMed ID: 15735047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Both CD4 and CD8 T cells mediate equally effective in vivo tumor treatment when engineered with a highly avid TCR targeting tyrosinase.
    Frankel TL; Burns WR; Peng PD; Yu Z; Chinnasamy D; Wargo JA; Zheng Z; Restifo NP; Rosenberg SA; Morgan RA
    J Immunol; 2010 Jun; 184(11):5988-98. PubMed ID: 20427771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chronic TCR-MHC (self)-interactions limit the functional potential of TCR affinity-increased CD8 T lymphocytes.
    Duong MN; Erdes E; Hebeisen M; Rufer N
    J Immunother Cancer; 2019 Nov; 7(1):284. PubMed ID: 31690351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation and characterization of HLA-A2 transgenic mice expressing the human TCR 1G4 specific for the HLA-A2 restricted NY-ESO-1
    Shenderov E; Kandasamy M; Gileadi U; Chen J; Shepherd D; Gibbs J; Prota G; Silk JD; Yewdell JW; Cerundolo V
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34088742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Transplantation of mouse HSCs genetically modified to express a CD4-restricted TCR results in long-term immunity that destroys tumors and initiates spontaneous autoimmunity.
    Ha SP; Klemen ND; Kinnebrew GH; Brandmaier AG; Marsh J; Hangoc G; Palmer DC; Restifo NP; Cornetta K; Broxmeyer HE; Touloukian CE
    J Clin Invest; 2010 Dec; 120(12):4273-88. PubMed ID: 21084750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cell receptor (TCR) structure of autologous melanoma-reactive cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineage-specific CTL clone.
    Sensi M; Salvi S; Castelli C; Maccalli C; Mazzocchi A; Mortarini R; Nicolini G; Herlyn M; Parmiani G; Anichini A
    J Exp Med; 1993 Oct; 178(4):1231-46. PubMed ID: 8376931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MHC class I-restricted recognition of a melanoma antigen by a human CD4+ tumor infiltrating lymphocyte.
    Nishimura MI; Avichezer D; Custer MC; Lee CS; Chen C; Parkhurst MR; Diamond RA; Robbins PF; Schwartzentruber DJ; Rosenberg SA
    Cancer Res; 1999 Dec; 59(24):6230-8. PubMed ID: 10626817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. T cell receptor transgenic lymphocytes infiltrating murine tumors are not induced to express foxp3.
    Quatromoni JG; Morris LF; Donahue TR; Wang Y; McBride W; Chatila T; Economou JS
    J Hematol Oncol; 2011 Nov; 4():48. PubMed ID: 22112546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential use of T cell receptor genes to modify hematopoietic stem cells for the gene therapy of cancer.
    Clay TM; Custer MC; Spiess PJ; Nishimura MI
    Pathol Oncol Res; 1999; 5(1):3-15. PubMed ID: 10079371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression.
    Voss RH; Kuball J; Engel R; Guillaume P; Romero P; Huber C; Theobald M
    Immunol Res; 2006; 34(1):67-87. PubMed ID: 16720899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A High-Avidity T-cell Receptor Redirects Natural Killer T-cell Specificity and Outcompetes the Endogenous Invariant T-cell Receptor.
    Landoni E; Smith CC; Fucá G; Chen Y; Sun C; Vincent BG; Metelitsa LS; Dotti G; Savoldo B
    Cancer Immunol Res; 2020 Jan; 8(1):57-69. PubMed ID: 31719055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bimodal ex vivo expansion of T cells from patients with head and neck squamous cell carcinoma: a prerequisite for adoptive cell transfer.
    Junker N; Andersen MH; Wenandy L; Dombernowsky SL; Kiss K; Sørensen CH; Therkildsen MH; Von Buchwald C; Andersen E; Straten PT; Svane IM
    Cytotherapy; 2011 Aug; 13(7):822-34. PubMed ID: 21428850
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor specific cytolysis by tumor infiltrating lymphocytes in breast cancer.
    Baxevanis CN; Dedoussis GV; Papadopoulos NG; Missitzis I; Stathopoulos GP; Papamichail M
    Cancer; 1994 Aug; 74(4):1275-82. PubMed ID: 7914469
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.
    Moore TV; Lyons GE; Brasic N; Roszkowski JJ; Voelkl S; Mackensen A; Kast WM; Le Poole IC; Nishimura MI
    Cancer Immunol Immunother; 2009 May; 58(5):719-28. PubMed ID: 18836717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. T cell activation and thymic tolerance induction require different adhesion intensities of the CD8 co-receptor.
    Knobloch M; Schönrich G; Schenkel J; Malissen M; Malissen B; Schmitt-Verhulst AM; Hämmerling GJ; Arnold B
    Int Immunol; 1992 Oct; 4(10):1169-74. PubMed ID: 1489732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE; Zachary DT; Osband ME
    Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Redirecting human CD4+ T lymphocytes to the MHC class I-restricted melanoma antigen MAGE-A1 by TCR alphabeta gene transfer requires CD8alpha.
    Willemsen R; Ronteltap C; Heuveling M; Debets R; Bolhuis R
    Gene Ther; 2005 Jan; 12(2):140-6. PubMed ID: 15496961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer.
    Chinnasamy N; Wargo JA; Yu Z; Rao M; Frankel TL; Riley JP; Hong JJ; Parkhurst MR; Feldman SA; Schrump DS; Restifo NP; Robbins PF; Rosenberg SA; Morgan RA
    J Immunol; 2011 Jan; 186(2):685-96. PubMed ID: 21149604
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.